Here are the year's breakthroughs for the climate and nature you might have missed.

A group of South Carolina senators plans to consider a proposal that could introduce the strictest abortion prohibitions and punishments in the nation.

Three paintings from public television legend Bob Ross have sold for over $600,000 at auction. The sales took place Tuesday at Bonhams in Los Angeles.

ANCHORAGE, Alaska (AP) — An immersion program that helps preserve an Alaska Native language has been a boon to children displaced by last month’s severe flooding in western Alaska.

The statue of Trump and Epstein holding hands mid-frolic wasn't the first anti-Trump artwork on the National Mall in recent months. But it was the first to be removed, despite having a permit.

One of the billionaire's investments has become a linchpin in the day-to-day machinery of Trump’s immigration enforcement apparatus.

U.S. President Donald Trump offered support to Benjamin Netanyahu on Wednesday, saying his trial should be canceled.

Help the Polar Bear at Point Defiance Zoo: End Suffering from Zoochosis

Bernard Rollin was a pioneer in animal rights. He left us with this scalding interview.

Robert F. Kennedy Jr., secretary of the US Department of Health and Human Services, is asking the US Centers for Disease Control and Prevention for an agencywide “scientific process” on treating measl...

As the second Trump administration sends U.S. science into upheaval, countless researchers are fighting for their futures

An experiment seven years in the making has uncovered new insights into the nature of consciousness and challenges two prominent, competing scientific theories.

The increasing incidence of antibiotic resistance and the decline in the discovery of novel antibiotics have resulted in a global health crisis, particularly, for the treatment of infections caused by Gram-negative bacteria, for which therapeutic dead-ends are alarming. Here, we identify and characterize a molecule, NM102, that displays antimicrobial activity exclusively in the context of infection. NM102 inhibits the activity of the non-essential Mutation Frequency Decline (Mfd) protein by competing with ATP binding to its active site. Inhibition of Mfd by NM102 sensitizes pathogenic bacteria to the host immune response and blocks infections caused by the clinically-relevant bacteria Klebsiella pneumoniae and Pseudomonas aeruginosa, without inducing host toxicity. Finally, NM102 inhibits the mutation and evolvability function of Mfd, thus reducing the bacterial capacity to develop antimicrobial resistance. These data provide a potential roadmap for the development of drugs to combat a